MHRA suspends use of hydroxyethyl starch (HES) intravenous (IV) drips


Intravenous news: MHRA report “The use of starch drips to treat critically ill patients and those undergoing surgery is to be suspended in the UK because their benefits no longer outweigh the risk of using them, the Medicines and Healthcare products Regulatory Agency (MHRA) announced today.

The drips are currently used in a range of clinical settings for treatment and prevention of low blood volume (hypovolaemia) and a steep drop in blood pressure (hypovolaemic shock), as well as for maintenance of adequate circulation during surgical procedures, should no longer be used.”

Main page


Leave A Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.